{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04170426",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CTX0019-001"
      },
      "Organization": {
        "OrgFullName": "Celltex Therapeutics Corporation",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis",
      "OfficialTitle": "Phase 1/2a Clinical Study for Subjects With Rheumatoid Arthritis (RA) Using Multiple Dose Intravenous Infusions of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs)"
    },
    "StatusModule": {
      "StatusVerifiedDate": "July 2021",
      "OverallStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "December 2021",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "December 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 2024",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "November 18, 2019",
      "StudyFirstSubmitQCDate": "November 18, 2019",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "November 20, 2019",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "July 22, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "July 23, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Celltex Therapeutics Corporation",
        "LeadSponsorClass": "INDUSTRY"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "Yes",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "This is an investigational new drug clinical trial for combined Phase 1 dose escalation study and Phase 2a randomized, placebo controlled and double blinded study using intravenous injection of autologous adipose stem cells (Celltex AdMSCs) for rheumatoid arthritis patients. All subjects are monitored for safety (adverse events/severe adverse events) and evaluated for RAPID3, DAS28 and ACR20 regarding AdMSCs up to 52 weeks study duration."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Rheumatoid Arthritis"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Sequential Assignment",
        "DesignInterventionModelDescription": "Combined Phase 1 dose escalation study and Phase 2a randomized, placebo controlled and double blinded study using autologous adipose stem cells (Celltex AdMSCs) for rheumatoid arthritis patients who failed disease-modifying antirheumatic drug (DMARDs).",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Quadruple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Care Provider",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "54",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Phase 1 ARM 0",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "9 subjects receive dose escalation of autologous AdMSCs via Intravenous infusion in Phase 1",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: autologous adipose derived stem cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase 2 ARM 1",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "30 subjects receive three doses of 2.0-2.86×10^6 cells/kg on day 1, 4 and 7 via Intravenous infusion in Phase 2a",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: autologous adipose derived stem cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Phase 2 ARM 2",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "15 subjects receive three doses of placebo on day 1, 4 and 7 via Intravenous infusion in Phase 2a",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: autologous adipose derived stem cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "autologous adipose derived stem cells",
            "InterventionDescription": "Culture expanded mesenchymal stem cells isolated from patient's own abdominal fat tissue",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Phase 1 ARM 0",
                "Phase 2 ARM 1",
                "Phase 2 ARM 2"
              ]
            },
            "InterventionOtherNameList": {
              "InterventionOtherName": [
                "Celltex-AdMSCs"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Adverse Events and Sever Adverse Events",
            "PrimaryOutcomeDescription": "The total number of adverse events and severe adverse events related and non-related with AdMSCs will be recorded to indicate the safety and tolerability.",
            "PrimaryOutcomeTimeFrame": "52 weeks"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Efficacy of Celltex AdMSCs",
            "SecondaryOutcomeDescription": "Proportion of ACR 20 patients (swollen joints, tender joints, patient assessment of pain, RAPID3, DAS28-CRP and blood inflammatory panel tests) in comparison between baseline and post-treatment follow-up data.",
            "SecondaryOutcomeTimeFrame": "52 weeks"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMust pass communicable disease screen tests for HIV, syphilis, Hepatitis B and C Consistent with American Rheumatism Association-European League Against Rheumatism (ACR/EULAR) 2010 rheumatoid arthritis classification criteria\nActive Rheumatoid Arthritis, see RA functional status of class I-IV\nPatients must meet at least one of the following: > 6 swollen joints and ≥ 6 involved joints (tenderness, swelling, deformity, pain on motion, or decreased motion) and morning stiffness ≥ 45 minutes based on 68 joint count.\nPatients must also meet at least one of the following: rheumatoid factor (RF) > 15 IU/mL or > 1:16, C-reactive protein (CRP) > 2.0 mg/dL, Erythrocyte Sedimentation Rate (ESR) > 30 mm/hour, and anti-cyclic citrullinated protein (Anti-CCP) > 20 U/mL, TNFα > 2.8 pg/mL.\nPatients must have failed anti-rheumatoid drug due to adverse event or inefficacy for at least 12 week and at least 4 weeks on stable dose of methotrexate ≤ 25 mg/week, or leflunomide ≤ 20 mg/day, or sulfasalazine ≤ 3 g/day, or steroids (Prednisone <10 mg/day).\nFor other medications, patients must be on the stable dose for at least 4 weeks prior to study entry in order to preclude changes to patient medication while participating on the study to ensure that a medication change could become a confounding factor in data interpretation.\nAll patients must be clinically stable with no significant changes in health status a minimum of at least 4 weeks prior to randomization and confirming patient eligibility\n\nExclusion Criteria:\n\nCurrent or prior to treatment\n\nParticipation in another clinical study (with use of another Investigational Medical Product) within 3 months prior to study treatment start\nEvidence of immune suppression related to prior/current therapy\n> 10% change in delivered monthly dose of anti-rheumatoid medications within 4 weeks prior to this stem cell infusion\nUse of a new or additional anti-rheumatoid medication within 6 weeks prior to this stem cell infusion\nUse of other stem cell therapy within 12 weeks prior to this stem cell therapy\nUnwillingness or inability to comply with study procedures\n\nConcurrent Conditions\n\nClinically active malignant disease\nSevere bladder or thrombotic disorder\nHistory of known pulmonary embolism or known secondary anti-phospholipid syndrome\nKnown or suspected hypersensitivity to any components used to culture or store the AdMSCs, e.g. sulfur or sulfonamide\nKnown or suspected antibodies to any components used to culture the AdMSCs, e.g. BSA and sulfur containing products (e.g., DMSO)\nActive infection at time of planned study treatment start\nAge related pathology likely to inhibit study participation or completion\nMajor trauma or surgery within 14 days of study treatment start\nMental condition rendering the subject (or the subject's legally acceptable representative[s]) unable to understand the nature, scope and possible consequences of the study\nAlcohol, drug, or medication abuse within one year before study treatment start\nAny condition that, in the Investigator's opinion, is likely to interfere with evaluation of the AdMSC therapy or satisfactory conduct of the study\nIrreversible severe end organ failure, such as heart failure/attack, stroke, liver and renal failure\nHeavy smokers, bed-bound patients, patients or family history with hypercoagulable status, such as protein C/protein S deficiency, factor V Leiden, prothrombin gene mutation, dysfibrinogenemia, etc.\n\nLaboratory Parameters\n\nHepatic impairment, defined as any of ALT, AST, LDH or bilirubin > 2 x the upper limit of normal (ULN) range according to local laboratory standards\nRenal impairment, defined as serum creatinine > 133 mmol/L (1.5 mg/dL)\nPositive virology/serology for human immunodeficiency virus (HIV), hepatitis B (HBsAg positive), hepatitis C and/or syphilis\n\nPregnancy / contraception\n\nPregnant, breastfeeding, or desire to become pregnant or unwilling to practice birth control during participation in the study duration, unless surgically sterilized or postmenopausal during the study",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Sally McGahee",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "7135546847",
            "CentralContactEMail": "smcgahee@celltexbank.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Derek W Guillory, MD",
            "OverallOfficialAffiliation": "Root Causes Medicine",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000001168",
            "ConditionMeshTerm": "Arthritis"
          },
          {
            "ConditionMeshId": "D000001172",
            "ConditionMeshTerm": "Arthritis, Rheumatoid"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007592",
            "ConditionAncestorTerm": "Joint Diseases"
          },
          {
            "ConditionAncestorId": "D000009140",
            "ConditionAncestorTerm": "Musculoskeletal Diseases"
          },
          {
            "ConditionAncestorId": "D000012216",
            "ConditionAncestorTerm": "Rheumatic Diseases"
          },
          {
            "ConditionAncestorId": "D000003240",
            "ConditionAncestorTerm": "Connective Tissue Diseases"
          },
          {
            "ConditionAncestorId": "D000001327",
            "ConditionAncestorTerm": "Autoimmune Diseases"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M3628",
            "ConditionBrowseLeafName": "Arthritis",
            "ConditionBrowseLeafAsFound": "Arthritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3632",
            "ConditionBrowseLeafName": "Arthritis, Rheumatoid",
            "ConditionBrowseLeafAsFound": "Rheumatoid Arthritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9773",
            "ConditionBrowseLeafName": "Joint Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11249",
            "ConditionBrowseLeafName": "Musculoskeletal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14197",
            "ConditionBrowseLeafName": "Rheumatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5475",
            "ConditionBrowseLeafName": "Collagen Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5616",
            "ConditionBrowseLeafName": "Connective Tissue Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3781",
            "ConditionBrowseLeafName": "Autoimmune Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC05",
            "ConditionBrowseBranchName": "Musculoskeletal Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          }
        ]
      }
    }
  }
}